The global point-of-care (PoC) market was valued at USD 18,219.4 million in 2016 and is projected to exhibit a CAGR of 9.2 percent from 2017–2025. PoC diagnostics offer advantages such as rapid diagnosis, increased access to innovative diagnostic tests even in remote areas, time and cost saving, and wide variety of diseases can be tested, and diagnosed under minimum amount of time. Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is expected to positively impact growth of point of care diagnostic market due to increasing demand form patients for rapid diagnosis and treatment.

For instance, according to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015, worldwide. Manufacturers are engaged in product innovation to minimize time require to perform test and costs associated with it along with improving medical outcomes. For instance, France based NG Biotech, and Australia based Atomo Diagnostics developed first fully integrated blood-based rapid test for detection of hCG levels in pregnancy in 2016. F. Hoffmann-La Roche AG launched PoC troponin test with improved accuracy at low concentrations to help diagnose heart attack patients at high mortality risk in 2015. Moreover, the company launched CoaguChek Pro II system to determine coagulation status of patients at all points of care in 2015. Alere, Inc. launched first-ever rapid diagnostic test, Malaria Ag P.f, for detection of asymptomatic malaria infection in May 2017.

Trinity Biotech plc. received CE marking for Uni-Gold H. pylori Antigen point-of-care test in 2014. The Uni-Gold H. pylori Antigen are a 15 min rapid test, used for diagnosis of Helicobacter pylori (H. pylori) infection and to monitor the effectiveness of treatment. Alere launched Alere iCup Rx Drug Screen through urine test for detecting commonly misused and abused prescription drugs in 2017. The test is a rapid urine test, which detects five of the commonly misused prescription drugs such as benzodiazepines, and buprenorphine. Moreover, Alere, Inc. along with its partner company GenPrime, Inc., launched point of care testing device, the xReader for work-place drug testing in 2016. In 2016, LifeScan, Inc. a Johnson & Johnson company launched new OneTouch Verio Flex blood glucose monitoring system with ColorSure technology, which is a simple, accurate and easy-to-use meter. It offers blood sugar test results for people with diabetes. – Coherent Market Research

10 Diagnostic Imaging Trends for 2018



Digital version